- Home
- CYCC vs ACET Comparison
CYCC vs ACET Comparison
Compare CYCC & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCC
- ACET
- Stock Information
- Founded
- CYCC 1992
- ACET 1947
- Country
- CYCC Malaysia
- ACET United States
- Employees
- CYCC N/A
- ACET N/A
- Industry
- CYCC Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- CYCC Health Care
- ACET Health Care
- Exchange
- CYCC Nasdaq
- ACET Nasdaq
- Market Cap
- CYCC 61.2M
- ACET 55.1M
- IPO Year
- CYCC N/A
- ACET N/A
- Fundamental
- Price
- CYCC $1.63
- ACET $0.72
- Analyst Decision
- CYCC
- ACET Buy
- Analyst Count
- CYCC 0
- ACET 6
- Target Price
- CYCC N/A
- ACET $6.00
- AVG Volume (30 Days)
- CYCC 191.0K
- ACET 764.4K
- Earning Date
- CYCC 05-15-2025
- ACET 05-06-2025
- Dividend Yield
- CYCC 147.24%
- ACET N/A
- EPS Growth
- CYCC N/A
- ACET N/A
- EPS
- CYCC N/A
- ACET N/A
- Revenue
- CYCC $14,000.00
- ACET N/A
- Revenue This Year
- CYCC $137.21
- ACET N/A
- Revenue Next Year
- CYCC N/A
- ACET N/A
- P/E Ratio
- CYCC N/A
- ACET N/A
- Revenue Growth
- CYCC N/A
- ACET N/A
- 52 Week Low
- CYCC $1.36
- ACET $0.45
- 52 Week High
- CYCC $49.34
- ACET $1.70
- Technical
- Relative Strength Index (RSI)
- CYCC 32.89
- ACET 53.94
- Support Level
- CYCC $1.36
- ACET $0.64
- Resistance Level
- CYCC $1.94
- ACET $0.72
- Average True Range (ATR)
- CYCC 0.43
- ACET 0.06
- MACD
- CYCC -0.07
- ACET 0.01
- Stochastic Oscillator
- CYCC 8.31
- ACET 60.07
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.